Equally important, it would require annual reports to Congress on clinical outcomes, research and success from innovative therapies so we could evaluate what works and establish those best practices Department-wide.
Require the Department of Veterans Affairs to submit annual reports to Congress on clinical outcomes, research, and success of innovative therapies for veterans.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
On March 27, 2026, Senator Tim Sheehy introduced the bipartisan Veterans Health Administration Novel Therapeutics Preparedness Act. This legislation aims to establish a dedicated Office of Novel Therapeutics within the Department of Veterans Affairs (VA) to enhance veterans' access to innovative health care. A key provision of the bill requires the VA to submit annual reports to Congress detailing clinical outcomes, research, and the success of emerging therapies for veterans.
legacy_unverified · Source version not recorded · locator unknown
04-30-2026 | S.4220 | Veterans Health Administration Novel Therapeutics Preparedness Act | Latest Action: Committee on Veterans' Affairs. Hearings held.
legacy_unverified · Source version not recorded · locator unknown
Mr. Sheehy (for himself, Mr. Gallego, Ms. Duckworth, and Mr. Boozman) introduced the following bill; which was read twice and referred to the Committee on Veterans' Affairs.
legacy_unverified · Source version not recorded · locator unknown
Sheehy's legislation page listed S.4220 with latest action as 'Committee on Veterans' Affairs. Hearings held' on the June 5 update, indicating committee activity but no enactment.
legacy_unverified · Source version not recorded · locator unknown
GovInfo records S.4220 as introduced in the Senate on March 26, 2026 and referred to the Committee on Veterans' Affairs.
legacy_unverified · Source version not recorded · locator unknown
The Senate office said the bipartisan bill would create a VA Office of Novel Therapeutics and require annual reports to Congress on clinical outcomes, research, and success of innovative therapies.
legacy_unverified · Source version not recorded · locator unknown
Sen. Tim Sheehy announced a bipartisan bill that would create a VA Office of Novel Therapeutics and require annual reports to Congress on clinical outcomes, research, and the success of innovative therapies for veterans.
legacy_unverified · Source version not recorded · locator unknown
The official bill record shows S. 4220 was introduced in the Senate on March 26, 2026, read twice, and referred to the Committee on Veterans' Affairs; the bill title and summary align with the VA reporting concept, but no enacted law appears here.
legacy_unverified · Source version not recorded · locator unknown
Sheehy's legislation page listed S. 4220 with latest action 'Committee on Veterans' Affairs. Hearings held' as of the page update, showing continued committee activity but no enactment of the annual-report requirement.
unverified · Source version 62673 · locator unknown
Sheehy's official legislation page, crawled during this refresh, lists S.4220, Veterans Health Administration Novel Therapeutics Preparedness Act, with an updated entry dated 08-18-2026 and latest action: Committee on Veterans' Affairs. Hearings held.
unverified · Source version 62690 · locator unknown
GovInfo lists H.R.8800 as Engrossed in House with last action date July 22, 2026. The House-engrossed text includes Sec. 1752 requiring the VA Under Secretary for Health to submit biannual reports to the House and Senate Veterans' Affairs Committees on emerging therapeutic interventions, including research activities, clinical outcomes and patient-reported outcomes, veteran enrollment, interagency coordination, and recommendations.
Assessments
Tim Sheehy introduced S.4220 in the 119th Congress to create a VA Office of Novel Therapeutics and require reports to Congress on clinical outcomes, research, and innovative therapy success. That materially matches the promise and advanced to a Veterans' Affairs Committee hearing, but current official-status evidence shows it has not been enacted and the related House NDAA language was only House-engrossed, not law. Because the promised reporting requirement is not binding federal policy, this is a failed but serious legislative attempt, not delivery.
Sheehy made a concrete and serious legislative attempt that directly matched the promise by introducing the bipartisan Veterans Health Administration Novel Therapeutics Preparedness Act, which would have required the VA to submit annual reports to Congress on clinical outcomes, research, and innovative therapies for veterans. But the available record shows the bill was introduced, referred to the Senate Committee on Veterans' Affairs, and later listed only as having hearings held as of June 5, 2026. There is no evidence that the reporting requirement was enacted into law or otherwise imposed on the VA, so the promised outcome was not delivered.
As a first-term U.S. senator, Tim Sheehy took a serious and concrete legislative step toward this promise by introducing the bipartisan Veterans Health Administration Novel Therapeutics Preparedness Act in March 2026, and the bill included the claimed requirement for annual VA reports to Congress on clinical outcomes, research, and innovative therapies. But the available record shows only introduction, referral, and committee hearings; there is no evidence that the reporting requirement was enacted or otherwise imposed on the VA. Under the federal office standard, that counts as a meaningful attempt but not delivery of the promised outcome.
Sheehy introduced S.4220, the Veterans Health Administration Novel Therapeutics Preparedness Act, during his current Senate term, and the bill includes the promised annual VA reporting requirement on clinical outcomes, research, and success of innovative therapies. However, the measure has not been enacted and the requirement is not in force; the latest available status shows committee activity only. This is a serious legislative attempt by the candidate, so it merits an effort badge, but not delivery of the promised outcome.
Senator Sheehy introduced legislation that would require the VA to submit annual reports on clinical outcomes and therapies, reflecting a serious attempt to deliver on the promise. However, there is no evidence the bill became law or that the requirement was enacted, so the outcome was not delivered despite significant legislative effort.